These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Aoki KR; Guyer B Eur J Neurol; 2001 Nov; 8 Suppl 5():21-9. PubMed ID: 11851731 [TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Callaway JE Clin Dermatol; 2004; 22(1):23-8. PubMed ID: 15158541 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Dessy LA; Fallico N; Mazzocchi M; Scuderi N Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology of botulinum toxin: differences between type A preparations. Rosales RL; Bigalke H; Dressler D Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology and immunology of botulinum neurotoxins. Aoki KR Int Ophthalmol Clin; 2005; 45(3):25-37. PubMed ID: 15970764 [No Abstract] [Full Text] [Related]
9. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Dressler D; Hallett M Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565 [TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin in pain treatment. Colhado OC; Boeing M; Ortega LB Rev Bras Anestesiol; 2009; 59(3):366-81. PubMed ID: 19488551 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology of botulinum neurotoxin serotype A. Wenzel RG Am J Health Syst Pharm; 2004 Nov; 61(22 Suppl 6):S5-10. PubMed ID: 15598004 [TBL] [Abstract][Full Text] [Related]
13. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Aoki KR Headache; 2003; 43 Suppl 1():S9-15. PubMed ID: 12887389 [TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Roger Aoki K Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646 [TBL] [Abstract][Full Text] [Related]
16. Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides. Sadick NS; Herman AR Dermatol Surg; 2003 Apr; 29(4):340-7. PubMed ID: 12656810 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology and clinical applications of botulinum toxins A and B. Thakker MM; Rubin PA Int Ophthalmol Clin; 2004; 44(3):147-63. PubMed ID: 15211183 [No Abstract] [Full Text] [Related]
18. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection. Cai BB; Francis J; Brin MF; Broide RS Neuroscience; 2017 Jun; 352():155-169. PubMed ID: 28389376 [TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of botulinum neurotoxin: Unexpected consequences. Hallett M Toxicon; 2018 Jun; 147():73-76. PubMed ID: 28803760 [TBL] [Abstract][Full Text] [Related]
20. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Sankhla C; Jankovic J; Duane D Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]